Editor: Johannes Kusters
Enhanced resistance against systemic Candida albicans infection in mice treated with C. albicans DNA
Article first published online: 28 JUN 2008
© 2008 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved
FEMS Immunology & Medical Microbiology
Volume 53, Issue 2, pages 231–236, July 2008
How to Cite
Dimitrova, P., Yordanov, M., Danova, S. and Ivanovska, N. (2008), Enhanced resistance against systemic Candida albicans infection in mice treated with C. albicans DNA. FEMS Immunology & Medical Microbiology, 53: 231–236. doi: 10.1111/j.1574-695X.2008.00421.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Received 14 October 2007; revised 21 January 2008; accepted 4 April 2008.First published online 28 May 2008.
- Candida albicans infection;
- C. albicans DNA;
- tyrphostin AG-490
In this study, double-stranded Candida albicans DNA was administered in systemic C. albicans infection in at dose of 20 μg per mouse at 4, 5 and 6 weeks of age. The level of IL-12 in serum was elevated as a result of yeast DNA treatment and correlated with lower mortality and decreased kidney and liver injury. Macrophage activation was demonstrated by an increase of nitric oxide (NO) and IL-12 production. These effects were Janus activation kinases (JAK)/signal transducer and activator of transcription (STAT) dependent as they were inhibited by selective JAK inhibitor tyrphostin AG-490. DNA influenced adaptive immune response through elevation of anti-Candida IgG antibody production in systemic C. albicans infection. Thus, C. albicans DNA augmented innate and adaptive immune responses against the pathogen.